The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 15, 2025

Filed:

Dec. 29, 2022
Applicants:

Providence Health & Services—oregon, Portland, OR (US);

Agonox, Inc., Portland, OR (US);

Inventors:

Andrew D. Weinberg, Portland, OR (US);

Ryan Montler, Camas, WA (US);

Thomas Duhen, Portland, OR (US);

Rebekka Duhen, Portland, OR (US);

Assignees:

Providence Health & Services—Oregon, Portland, OR (US);

AgonOx, Inc., Portland, OR (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 48/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C12N 5/0636 (2013.01); C12N 15/1003 (2013.01); C12N 15/85 (2013.01); A61K 48/00 (2013.01); A61K 2239/46 (2023.05); C12N 2500/32 (2013.01); C12N 2501/2315 (2013.01); C12N 2502/00 (2013.01);
Abstract

Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8CD39CD103T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8CD39CD103T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8CD39CD103T cells. In addition, methods are disclosed for expanding CD8CD39CD103T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8CD39CD103T cells in a biological sample from a subject.


Find Patent Forward Citations

Loading…